Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology
Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.
- Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.
- Prior to serving as Chief Scientific Officer of CureVac, Dr. Splawski spent fifteen years at the Novartis Institutes for BioMedical Research (NIBR).
- Dr. Splawski has a PhD in Human Genetics from the University of Utah and an MSc in Biotechnology from Sofia University.
- Splawski is recognized as a leading figure in the development of complex human genetic tests, protein biologics, and RNA therapies, and we are excited to welcome him to Yarrow,” said Peter Fong, PhD, Chief Executive Officer of Yarrow Biotechnology and Partner and Chief Development Officer at RTW.